Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Permanent diabetes due to a mutation in KCNJ11 (KIR6.2)~* Patients successfully transferred from insulin to sulfonylurea~* Transferred to sulfonylurea treatment before November 1, 2006 (ie 9 years off insulin)~* Willing and able to provide informed consent (parents if younger than 16 years of age)~Exclusion Criteria:~* Permanent diabetes not due to a mutation in KCNJ11 (KIR6.2)~* Patients not successfully transferred from insulin to sulfonylurea~* Transferred to sulfonylurea treatment after November 1, 2006 (ie less than 9 years off insulin)~* Not willing or able to provide informed consent (parents if younger than 16 years of age)

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: Sulfonylurea (Type: EXPERIMENTAL): Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to glucagon have been tested.

Based on this trial design, predict the completion outcome and termination type (if applicable).